MARKET

NVO

NVO

Novo-Nordisk A/S
NYSE
128.64
+3.38
+2.70%
After Hours: 128.90 +0.26 +0.20% 19:59 04/23 EDT
OPEN
126.57
PREV CLOSE
125.26
HIGH
128.76
LOW
126.34
VOLUME
3.70M
TURNOVER
0
52 WEEK HIGH
138.28
52 WEEK LOW
74.66
MARKET CAP
573.93B
P/E (TTM)
46.67
1D
5D
1M
3M
1Y
5Y
What to Watch in the Day Ahead - Wednesday, April 24
Meta Platforms' revenue is expected to grow 26% as AI investments drive higher engagement at Instagram. Boeing expected to report a much higher cash burn and its first revenue fall in seven quarters. AT&T expected to post weak subscriber additions in the first quarter. Census Bureau to report orders for durable goods rose 2.5% in March.
Reuters · 10h ago
ANALYSIS-UK stocks may finally be back in fashion
London's FTSE-100 hit a record high on Tuesday. Britain's benchmark stock index touched a peak of 8,076.52, surpassing its previous high from February 2023. The FTSe-100 has long underperformed compared to rival indexes. But rising commodity prices, a weaker pound, and UK growth are encouraging investors to return to UK stocks.
Reuters · 11h ago
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 11h ago
TikTok to restrict weight loss drug promotion
Seeking Alpha · 13h ago
PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns
VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF's top holdings include Eli Lilly, Novo Nordisk, and Johnson & Johnson. The fund has been in an uptrend since late last year and is currently trading at a level that presents a buying opportunity.
Seeking Alpha · 20h ago
Why Novo Nordisk Topped the Market Today
Danish pharmaceutical company Novo Nordisk bought 207,000 of its own shares last week. The company's shares rose more than 2% on the day. The Danish-based company is the company behind popular weight loss and diabetes drugs. It has a one-year stock buyback program.
The Motley Fool · 1d ago
Wall Street Lunch: Big Tech Bearishness?
UBS downgrades Apple, Amazon, Google, Meta, Microsoft and Nvidia. UBS sounded a warning on its list of Big 6 tech companies. Five risks to the $2 trillion private credit market. Verizon reported first-quarter earnings that topped estimates. Looking ahead to earnings and Verizon.
Seeking Alpha · 1d ago
Eli Lilly to acquire manufacturing facility from Nexus Pharma
Eli Lilly to acquire manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines. Lilly expects production at the facility based in Pleasant Prairie, Wisconsin, to begin at the end of 2025. Soaring demand for GLP-1 agonists has led to constrained supply for drugmakers.
Reuters · 1d ago
More
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers Novo Nordisk A/S (ADR) stock information, including NYSE: NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.